SPY336.84+0.01 0.00%
DIA279.80+0.38 0.14%
IXIC11,019.30-23.20 -0.21%

Wells Fargo Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $16

Wells Fargo downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $24 to $16.

Benzinga · -

Wells Fargo downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $24 to $16.